Key Points
- Simrat Randhawa, EVP of Dianthus, sold a total of 196,538 shares on Nov 13–14 for roughly $7.38 million, leaving her with 4,000 shares — a 95.63% reduction in her position.
- Shares rose about 15.1% to $40.85 on heavy volume (~1.57M vs. avg 505k), valuing the company near $1.75 billion and close to its one‑year high of $41.15.
- Dianthus recently missed quarterly EPS estimates (‑$0.97 vs. ‑$0.86) and revenue, showing steep negative margins, yet analysts maintain a consensus "Moderate Buy" with an average target of $63.43.
Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) EVP Simrat Randhawa sold 87,507 shares of the company's stock in a transaction on Thursday, November 13th. The stock was sold at an average price of $36.81, for a total transaction of $3,221,132.67. Following the completion of the sale, the executive vice president owned 4,000 shares of the company's stock, valued at approximately $147,240. The trade was a 95.63% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Simrat Randhawa also recently made the following trade(s):
- On Friday, November 14th, Simrat Randhawa sold 109,031 shares of Dianthus Therapeutics stock. The stock was sold at an average price of $38.14, for a total transaction of $4,158,442.34.
Dianthus Therapeutics Trading Up 15.1%
Shares of NASDAQ DNTH traded up $5.35 during midday trading on Friday, hitting $40.85. The company's stock had a trading volume of 1,574,910 shares, compared to its average volume of 505,087. The firm has a market capitalization of $1.75 billion, a price-to-earnings ratio of -11.74 and a beta of 1.56. The stock has a fifty day moving average price of $35.94 and a 200 day moving average price of $25.62. Dianthus Therapeutics, Inc. has a one year low of $13.36 and a one year high of $41.15.
Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last posted its earnings results on Wednesday, November 5th. The company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.11). Dianthus Therapeutics had a negative return on equity of 33.02% and a negative net margin of 4,106.04%.The business had revenue of $0.40 million for the quarter, compared to analysts' expectations of $0.58 million. On average, equities research analysts predict that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
DNTH has been the subject of several analyst reports. Weiss Ratings restated a "sell (d-)" rating on shares of Dianthus Therapeutics in a report on Wednesday, October 8th. Guggenheim increased their price target on shares of Dianthus Therapeutics from $92.00 to $100.00 and gave the stock a "buy" rating in a research report on Tuesday, September 9th. Raymond James Financial reiterated an "outperform" rating and set a $63.00 price objective (up from $56.00) on shares of Dianthus Therapeutics in a research note on Tuesday, September 9th. HC Wainwright boosted their price objective on Dianthus Therapeutics from $40.00 to $47.00 and gave the company a "buy" rating in a research report on Monday, November 10th. Finally, Robert W. Baird upped their target price on shares of Dianthus Therapeutics from $50.00 to $67.00 and gave the stock an "outperform" rating in a research report on Tuesday, September 9th. Nine research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $63.43.
Get Our Latest Analysis on DNTH
Hedge Funds Weigh In On Dianthus Therapeutics
Large investors have recently made changes to their positions in the business. Vestal Point Capital LP raised its position in shares of Dianthus Therapeutics by 88.2% in the 2nd quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company's stock valued at $59,616,000 after purchasing an additional 1,499,931 shares during the last quarter. RA Capital Management L.P. lifted its holdings in Dianthus Therapeutics by 53.6% during the first quarter. RA Capital Management L.P. now owns 2,866,733 shares of the company's stock valued at $52,003,000 after purchasing an additional 1,000,333 shares in the last quarter. Wellington Management Group LLP boosted its stake in shares of Dianthus Therapeutics by 3,366.9% in the third quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company's stock worth $101,431,000 after acquiring an additional 2,503,311 shares during the last quarter. Octagon Capital Advisors LP grew its stake in Dianthus Therapeutics by 11.0% during the 1st quarter. Octagon Capital Advisors LP now owns 2,341,667 shares of the company's stock valued at $42,478,000 after acquiring an additional 231,500 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in shares of Dianthus Therapeutics by 13.6% during the 3rd quarter. Vanguard Group Inc. now owns 1,642,198 shares of the company's stock worth $64,620,000 after acquiring an additional 196,117 shares during the period. 47.53% of the stock is owned by institutional investors and hedge funds.
Dianthus Therapeutics Company Profile
(
Get Free Report)
Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
